ViCentra Extends Series D to $98 Million to Accelerate European Scale-Up and U.S. Market Entry

New updates have been reported about ViCentra.

ViCentra has expanded its Series D financing round to $98 million after securing an additional $13 million from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, alongside increased backing from existing investor Innovation Industries. The Utrecht-based medical device company, which develops and commercializes the Kaleido insulin patch pump system, will deploy the new capital to ramp up manufacturing capacity, strengthen commercial execution in Germany, the Netherlands, and France, and advance preparations for U.S. market access for its next-generation Kaleido system. The extension follows the $85 million raised in September 2025 and reflects sustained investor confidence in ViCentra’s strategy, commercial traction, and operational performance. In 2025, the company doubled its user base to more than 4,000 patients, driving strong revenue growth and building critical scale in Germany—the world’s second-largest insulin pump market—as well as in its home market and France.

CEO Tom Arnold said the company’s goal for 2026 is to convert current high demand into satisfied users through quality and performance while nearly tripling its European user base by year-end, underscoring an aggressive growth agenda underpinned by expanded production and market penetration. The funding strengthens ViCentra’s position in the fast-growing insulin delivery segment, where its Kaleido patch pump competes on miniaturization, dosing precision, and lifestyle-focused design. The capital also supports regulatory and commercial readiness for U.S. entry, a key future growth driver. ViCentra’s leadership team, including Arnold, plans to meet investors and potential partners during the J.P. Morgan Healthcare Conference week in San Francisco and at the LSI USA ’26 Emerging Medtech Summit, signaling ongoing focus on strategic partnerships and potential future financing or commercial collaborations as the company scales.